Opioid Addiction: Promising Drug Announced By This Medical Company
BioXcel Therapeutics' BXCL501 Shows Promise in NIDA-funded Trial for Opioid Use Disorder Treatment.
BioXcel Therapeutics, a leading clinical-stage biopharmaceutical company, recently announced an important update on the National Institute on Drug Abuse (NIDA)-funded trial of its drug BXCL501 for potential treatment of Opioid Use Disorder (OUD).
BXCL501, a proprietary sublingual film of dexmedetomidine, is currently bein…